First of all, use of Relistor in advanced chronic pain is unaffected. An oral formulation will be preferred over sub-cutaneous injection, so there is reason to advance oral. Second, we don't know what the additional clinical data Comment means, so even if another clinical trial is needed, an oral formulation will be the one used since that will maximize patient usage.
Market Data 
Markets 
AI
